ATR and lung cancer: We sought to elaborate on these two observations by assessing the effects of the ATR inhibitor, VX-970, and the Chk1 inhibitor, AZD7762, on an extensive panel of lung cancer cell lines in combination with five DNA damaging drugs from various mechanistic classes.